Detalles de la búsqueda
1.
Gastrin analogue administration adds no significant glycaemic benefit to a glucagon-like peptide-1 receptor agonist acutely or after washout of both analogues.
Diabetes Obes Metab
; 21(7): 1606-1614, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30848033
2.
An assessment of the central disposition of intranasally administered insulin lispro in the cerebrospinal fluid of healthy volunteers and beagle dogs.
Drug Deliv Transl Res
; 7(1): 11-15, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27553192
3.
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Diabetes Care
; 39(7): 1241-9, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26681715
4.
Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial.
Arch Intern Med
; 163(19): 2277-82, 2003 Oct 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-14581245
5.
Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1ß antibody, in patients with type 2 diabetes.
Diabetes Care
; 36(8): 2239-46, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23514733
6.
Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Diabetes Care
; 40(6): 808, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28420698
7.
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Diabetes Care
; 39(11): e199-e200, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27926898
Resultados
1 -
7
de 7
1
Próxima >
>>